Recent Developments in Food and Drug Law, 2014 ed.: Leading Lawyers on Dealing with Increased Enforcement, Keeping Up-To-Date with FDA Requirements, and Developing Compliance Practices (Inside the Minds)

Recent Developments in Food and Drug Law, 2014 ed.: Leading Lawyers on Dealing with Increased Enforcement, Keeping Up-To-Date with FDA Requirements, and Developing Compliance Practices (Inside the Minds)

by Multiple Authors
     
 

Recent Developments in Food and Drug Law provides an authoritative, insider's perspective on adapting to major changes in FDA regulations and enforcement procedures. Featuring experienced partners from law firms across the nation, these experts guide the reader through the rise of FDA inspections and propose key strategies for helping clients manage compliance

See more details below

Overview

Recent Developments in Food and Drug Law provides an authoritative, insider's perspective on adapting to major changes in FDA regulations and enforcement procedures. Featuring experienced partners from law firms across the nation, these experts guide the reader through the rise of FDA inspections and propose key strategies for helping clients manage compliance issues. These top lawyers offer advice on recognizing the triggers for investigations, responding to warning letters, and establishing an internal audit system. From navigating emerging trends in labeling practices to analyzing developments in pharmaceutical regulations, these experts emphasize the need to keep abreast of the FDA's increased safety concerns. The different niches represented and the breadth of perspectives presented enable readers to get inside some of the great legal minds of today, as these experienced lawyers offer up their thoughts on the keys to success within this dynamic area of law.

Inside the Minds provides readers with proven business and legal intelligence from leading C-Level executives and lawyers. Each chapter offers thought leadership and expert analysis on an industry, profession, or topic, providing a future-oriented perspective and proven strategies for success. Each author has been selected based on their experience and C-Level standing within the business and legal communities.

Chapters Include:

1. Bryan M. Haynes, Partner, Troutman Sanders LLP—"Understanding the Tobacco Control Act and FDA Investigative Process"
2. Ralph S. Tyler, Partner, Venable LLP—"Avoiding FDA Compliance Problems and Managing Them When They Occur"
3. David Abramowitz, Partner, Locke Lord LLP—"Keeping an Eye on FDA's Increased Focus on Safety and Efficacy"
4. Shahnam Sharareh, PharmD, JD, Partner, Fox Rothschild LLP—"New Food and Drug Law Enforcement Challenges: Where Do We Stand?"
5. Carey B. Nuttall, Partner, Patton Boggs LLP—"Pharmacy Compounding Issues in Today's Marketplace"
6. Brandon W. Neuschafer, Partner, Bryan Cave LLP—"Recent Developments in Food Labeling"
7. Roger Morris and Lisa Davis, Partners, Quarles & Brady LLP—"Generic Drugs and Biosimilars Lower Costs and Raise Legal Questions"
8. Theodora McCormick, Partner, Sills Cummis & Gross PC—"Food Advertising and Labeling Trends Spark Concerns About Compliance and Litigation"
9. Lisa Mueller, Partner, Michael Best & Friedrich—"Helping Clients Understand Biosimilar Product Regulations and the Biosimilar Litigation Process"
10. Suzan Onel, Partner, K&L Gates LLP—"Where the "App" World and FDA Collide: Current Status of the FDA's Regulation of Medical Device Software and Mobile Medical Apps"
11. Lauren A. Tulli, Member Attorney, Cozen O'Connor—"A Prescription for Responsibility: the FDA Looks to Expand the Scope of Potential Liability for Drug Company Officials"
12. Michael A. Walsh, Partner, Strasburger & Price LLP—"Net Impression: FDA's Old World Approach to a New World Opportunity"

Appendices Include:

Appendix A: Distributors—Have Your Suppliers Complied with the FDA's Registration and Filing Requirements?
Appendix B: FDA Issues "Guidance" on Exemptions from Substantial Equivalence Requirements
Appendix C: FDA Issues Draft Guidance on Demonstrating Substantial Equivalence
Appendix D: FDA Issues Draft Guidance on Applications for Premarket Review of New Tobacco Products
Appendix E: Lorillard Pursues FDA Citizen Petition to Obtain Approval of New Tobacco Products
Appendix F: Court Enjoins Law Requiring Graphic Cigarette Warnings
Appendix G: FDA Responds to Court Ruling on Graphic Warning Labels
Appendix H: Supreme Court Declines to Hear Challenge to FDA Graphic Warning Label Requirement
Appendix I: Congress Again Urges FDA to Regulate Cigars and Pipe Tobacco
Appendix J: Are Cigars with "Characterizing Flavors" Next on the Public Health Crusade's Hit List?
Appendix K: Obama Administration Includes New Tobacco Regulations in Regulatory Agenda
Appendix L: Current Good Manufacturing Practices—An Overlooked Requirement with Far Reaching Consequences
Appendix M: What is an Unacceptable Tobacco Brand Name Sponsorship Under FDA's Regulations?
Appendix N: FDA Issues Draft Guidance on Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products
Appendix O: FDA Issues Draft Guidance on Submitting Applications for Modified Risk Tobacco Products
Appendix P: Federal Court Allows TPSAC Challenge to Proceed
Appendix Q: New Tobacco Czar Assumes the Reins at FDA
Appendix R: Compliance Policy Guides Manual: Sec. 460.200 Pharmacy Compounding
Appendix S: Pharmaceutical Compounding Quality and Accountability Act
Appendix T: Bipartisan HELP Senators Introduce Major Effort to Clarify Oversight of Compounding Pharmacies; Help Ensure Consumer Safety
Appendix U: Excerpts of Draft Guidance for Industry and Food and Drug Administration Staff: Mobile Medical Applications, July 21, 2011
Appendix V: Excerpt of FDA's Statement: Identifying an MDDS, April 19, 2011

Read More

Product Details

ISBN-13:
9780314291196
Publisher:
Thomson Reuters Westlaw; Aspatore
Publication date:
11/01/2013
Pages:
312
Product dimensions:
5.50(w) x 8.40(h) x 0.80(d)

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >